title: Pushback on Zaltrap's price highlights sensitive end-of-life issue.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Dalzell
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D002173:Cancer Care Facilities / Q000191:economics / Q000592:standards; D014487:Centers for Medicare and Medicaid Services, U.S. / Q000191:economics / Q000592:standards; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics* / Q000941:ethics; D005572:Formularies, Hospital as Topic / Q000592:standards; D006801:Humans; D009362:Neoplasm Metastasis; D016019:Survival Analysis; D013727:Terminal Care / Q000191:economics* / Q000592:standards; D013810:Therapeutic Equivalency; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents